The Next New Wave In Genome Analysis

Sequencing may arguably be the premier technology of the eighties and nineties, but it has its shortcomings. For projects requiring frequent sampling or high sensitivity, conventional sequencing can be too labor intensive and expensive for laboratories outside the dedicated, high throughput sequencing centers. But a new technology is on the horizon--actually well over the horizon--that can provide genetic information simply and quickly. The discovery of a unique class of structure-specific end

Written byLaura De Francesco
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

Sequencing may arguably be the premier technology of the eighties and nineties, but it has its shortcomings. For projects requiring frequent sampling or high sensitivity, conventional sequencing can be too labor intensive and expensive for laboratories outside the dedicated, high throughput sequencing centers. But a new technology is on the horizon--actually well over the horizon--that can provide genetic information simply and quickly.

The discovery of a unique class of structure-specific endonucleases, or Cleavase® enzymes, has paved the way for the development of a novel set of molecular genetics assays (for review of structure specific nucleases, see M. Lieber, BioEssays, 19:233-40, 1997). One such assay, the CFLP® assay, is based on the ability of the Cleavase enzyme to recognize DNA secondary structures that form as DNA cools following brief thermal denaturation and to cut these structures, creating a unique "fingerprint" pattern of bands. (V. Lyamichev, M. Brow, and J. Dahlberg, Science ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies